. 2020 Nov 19;10(11):e039057. doi: 10.1136/bmjopen-2020-039057

Table 3.

Deterministic results per patient of the base case and scenario analyses in a cohort of 1000 patients with cancer (2019, euros)

	Costs	QALYs	ΔCosts	ΔQALYs	ICER
Base case analysis: 5-year time horizon from societal perspective
Rivaroxaban	€3139	2.459	−€1476	0.012	Rivaroxaban dominant
Dalteparin	€4615	2.448	−€1476	0.012	Rivaroxaban dominant
Scenario 1: 6-month time horizon from societal perspective
Rivaroxaban	€1361	0.304	−€1312	0.004	Rivaroxaban dominant
Dalteparin	€2673	0.300	−€1312	0.004	Rivaroxaban dominant
Scenario 2: base case analysis from healthcare payer’s perspective
Rivaroxaban	€2942	2.459	−€1496	0.012	Rivaroxaban dominant
Dalteparin	€4438	2.448	−€1496	0.012	Rivaroxaban dominant
Scenario 3: base case analysis with dalteparin dose of 12 500 IU
Rivaroxaban	€3139	2.459	−€1079	0.012	Rivaroxaban dominant
Dalteparin	€4218	2.448	−€1079	0.012	Rivaroxaban dominant
Scenario 4: base case analysis with dalteparin dose of 18 000 IU
Rivaroxaban	€3139	2.459	−€1898	0.012	Rivaroxaban dominant
Dalteparin	€5037	2.448	−€1898	0.012	Rivaroxaban dominant
Scenario 5: scenario one with treatment duration based on Streiff et al¹⁷
Rivaroxaban	€1299	0.289	−€702	0.016	Rivaroxaban dominant
Dalteparin	€2001	0.273	−€702	0.016	Rivaroxaban dominant
Scenario 6: base case analysis using drug-specific distributions for the types of VTE and MB
Rivaroxaban	€3065	2.463	−€1815	0.037	Rivaroxaban dominant
Dalteparin	€4880	2.425	−€1815	0.037	Rivaroxaban dominant

ICER, incremental cost-effectiveness ratio; IU, international units; MB, major bleeding; QALY, quality adjusted life-years; VTE, venous thromboembolism.